“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings

Senthil Selvaraj; Deepak L. Bhatt; Gregg W. Stone; C. Michael Gibson; Ph Gabriel Steg; Christian W. Hamm; Matthew J. Price; Efthymios N. Deliargyris; Jayne Prats; Kenneth W. Mahaffey; Harvey D. White; Robert A. Harrington

doi:10.1016/j.jacc.2016.08.023

“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings

Senthil Selvaraj, Deepak L. Bhatt, Gregg W. Stone, C. Michael Gibson, Ph Gabriel Steg, Christian W. Hamm, Matthew J. Price, Efthymios N. Deliargyris, Jayne Prats, Kenneth W. Mahaffey, Harvey D. White, Robert A. Harrington

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	2385-2387
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	68
Issue number	21
DOIs	https://doi.org/10.1016/j.jacc.2016.08.023
State	Published - 29 Nov 2016

Access to Document

10.1016/j.jacc.2016.08.023

Cite this

Selvaraj, S., Bhatt, D. L., Stone, G. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Deliargyris, E. N., Prats, J., Mahaffey, K. W., White, H. D., & Harrington, R. A. (2016). “Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. Journal of the American College of Cardiology, 68(21), 2385-2387. https://doi.org/10.1016/j.jacc.2016.08.023

@article{b7e1ce0950b24bbaa7f13e869e9aa50d,

title = "“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings",

author = "Senthil Selvaraj and Bhatt, {Deepak L.} and Stone, {Gregg W.} and Gibson, {C. Michael} and Steg, {Ph Gabriel} and Hamm, {Christian W.} and Price, {Matthew J.} and Deliargyris, {Efthymios N.} and Jayne Prats and Mahaffey, {Kenneth W.} and White, {Harvey D.} and Harrington, {Robert A.}",

note = "Funding Information: Please note: CHAMPION PHOENIX was sponsored by The Medicines Company. Dr. Bhatt is on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; is on the Board of Directors of Boston VA Research Institute, Society of Cardiovascular Patient Care; is the Chair of the American Heart Association Quality Oversight Committee and the VA CART Research and Publications Committee; is on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News; acc.org ), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today{\textquoteright}s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); is the Deputy Editor of Clinical Cardiology; is the Vice-Chair of the NCDR-ACTION Registry Steering Committee; has received research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, The Medicines Company (including for his role as co-chair of the CHAMPION trials); has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald{\textquoteright}s Heart Disease); is a site co-investigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee of the American College of Cardiology; and has performed unfunded research for FlowCo, PLx Pharma, and Takeda. Dr. Gibson has received research support from The Medicines Company. Dr. Steg has received research grants from Merck, Sanofi, and Servier; and has received speaking or consulting fees from Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL-Behring, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Lilly, Merck Novartis, Pfizer, Regeneron, Sanofi, Servier, and The Medicines Company. Dr. Hamm has received speaker{\textquoteright}s fees and is on the advisory boards of AstraZeneca, Lilly, and Daiichi-Sankyo. Dr. Price has received consulting fees and honoraria from ACIST Medical, AstraZeneca, Boston Scientific, The Medicines Company, Medtronic, and St. Jude Medical; and speaker fees and honoraria from AstraZeneca, Abbott Vascular, The Medicines Company, and St. Jude Medical. Drs. Deliargyris and Prats are employees of The Medicines Company. Dr. Mahaffey has received research funding from Amgen, Daiichi, Johnson & Johnson, Medtronic, Merck, St. Jude Medical, and Tenax; has received consultant Fees from American College of Cardiology, AstraZeneca, BAROnova, Bayer, Boehringer-Ingelheim, Bio2 Medical, Bristol-Myers Squibb, Cubist, Eli Lilly, Elsevier, Epson, Forest, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Mt. Sinai, Myokardia, Omthera, Portola, Purdue, Springer Publishing, The Medicines Company, Theravance, Vindico, and WebMD; and has stock in BioPrint Fitness. Dr. White has received honoraria from AstraZeneca; and has received research funding from Sanofi, Eli Lilly, National Health Institute, GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics, Elsai Inc, DalGen Products and Services, and Daiichi Sankyo Pharma Development. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. A full list of the CHAMPION PHOENIX Investigators can be found in Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303–13. The authors thank Steven E. Elkin, MS, and Debra Bernstein, PhD, of The Medicines Company for their statistical support, along with Yuyin Liu, MS, of the Harvard Clinical Research Institute for independent verification of the analyses. The Harvard Clinical Research Institute received funding from The Medicines Company for these analyses. ",

year = "2016",

month = nov,

day = "29",

doi = "10.1016/j.jacc.2016.08.023",

language = "English",

volume = "68",

pages = "2385--2387",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "21",

}

Selvaraj, S, Bhatt, DL, Stone, GW, Gibson, CM, Steg, PG, Hamm, CW, Price, MJ, Deliargyris, EN, Prats, J, Mahaffey, KW, White, HD & Harrington, RA 2016, '“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings', Journal of the American College of Cardiology, vol. 68, no. 21, pp. 2385-2387. https://doi.org/10.1016/j.jacc.2016.08.023

TY - JOUR

T1 - “Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction

T2 - CHAMPION PHOENIX Findings

AU - Selvaraj, Senthil

AU - Bhatt, Deepak L.

AU - Stone, Gregg W.

AU - Gibson, C. Michael

AU - Steg, Ph Gabriel

AU - Hamm, Christian W.

AU - Price, Matthew J.

AU - Deliargyris, Efthymios N.

AU - Prats, Jayne

AU - Mahaffey, Kenneth W.

AU - White, Harvey D.

AU - Harrington, Robert A.

N1 - Funding Information: Please note: CHAMPION PHOENIX was sponsored by The Medicines Company. Dr. Bhatt is on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; is on the Board of Directors of Boston VA Research Institute, Society of Cardiovascular Patient Care; is the Chair of the American Heart Association Quality Oversight Committee and the VA CART Research and Publications Committee; is on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News; acc.org ), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); is the Deputy Editor of Clinical Cardiology; is the Vice-Chair of the NCDR-ACTION Registry Steering Committee; has received research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, The Medicines Company (including for his role as co-chair of the CHAMPION trials); has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); is a site co-investigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee of the American College of Cardiology; and has performed unfunded research for FlowCo, PLx Pharma, and Takeda. Dr. Gibson has received research support from The Medicines Company. Dr. Steg has received research grants from Merck, Sanofi, and Servier; and has received speaking or consulting fees from Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL-Behring, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Lilly, Merck Novartis, Pfizer, Regeneron, Sanofi, Servier, and The Medicines Company. Dr. Hamm has received speaker’s fees and is on the advisory boards of AstraZeneca, Lilly, and Daiichi-Sankyo. Dr. Price has received consulting fees and honoraria from ACIST Medical, AstraZeneca, Boston Scientific, The Medicines Company, Medtronic, and St. Jude Medical; and speaker fees and honoraria from AstraZeneca, Abbott Vascular, The Medicines Company, and St. Jude Medical. Drs. Deliargyris and Prats are employees of The Medicines Company. Dr. Mahaffey has received research funding from Amgen, Daiichi, Johnson & Johnson, Medtronic, Merck, St. Jude Medical, and Tenax; has received consultant Fees from American College of Cardiology, AstraZeneca, BAROnova, Bayer, Boehringer-Ingelheim, Bio2 Medical, Bristol-Myers Squibb, Cubist, Eli Lilly, Elsevier, Epson, Forest, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Mt. Sinai, Myokardia, Omthera, Portola, Purdue, Springer Publishing, The Medicines Company, Theravance, Vindico, and WebMD; and has stock in BioPrint Fitness. Dr. White has received honoraria from AstraZeneca; and has received research funding from Sanofi, Eli Lilly, National Health Institute, GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics, Elsai Inc, DalGen Products and Services, and Daiichi Sankyo Pharma Development. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. A full list of the CHAMPION PHOENIX Investigators can be found in Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303–13. The authors thank Steven E. Elkin, MS, and Debra Bernstein, PhD, of The Medicines Company for their statistical support, along with Yuyin Liu, MS, of the Harvard Clinical Research Institute for independent verification of the analyses. The Harvard Clinical Research Institute received funding from The Medicines Company for these analyses.

PY - 2016/11/29

Y1 - 2016/11/29

UR - http://www.scopus.com/inward/record.url?scp=84997610343&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.08.023

DO - 10.1016/j.jacc.2016.08.023

M3 - Letter

C2 - 27591042

AN - SCOPUS:84997610343

SN - 0735-1097

VL - 68

SP - 2385

EP - 2387

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 21

ER -